Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.
Mol. Ther. 21, 2032-2042 (2013)
Recombinant vesicular stomatitis virus (VSV) shows promise for the treatment of hepatocellular carcinoma (HCC), but its safety and efficacy when administered in a setting of hepatic fibrosis, which occurs in the majority of clinical cases, is unknown. We hypothesized that VSV could provide a novel benefit to the underlying fibrosis, due to its ability to replicate and cause cell death specifically in activated hepatic stellate cells. In addition to the ability of VSV to produce a significant oncolytic response in HCC-bearing rats in the background of thioacetamide-induced hepatic fibrosis without signs of hepatotoxicity, we observed a significant downgrading of fibrosis stage, a decrease in collagen content in the liver, and modulation of gene expression in favor of fibrotic regression. Together, this work suggests that VSV is not only safe and effective for the treatment of HCC with underlying fibrosis, but it could potentially be developed for clinical application as a novel antifibrotic agent.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Vesicular Stomatitis-virus ; Hepatic Stellate Cells ; Apoptosis ; Cirrhosis ; Reversal ; Epidemiology ; Inhibition ; Activation ; Expression ; Diagnosis
ISSN (print) / ISBN
1525-0016
e-ISSN
1525-0024
Journal
Molecular Therapy
Quellenangaben
Volume: 21,
Issue: 11,
Pages: 2032-2042
Publisher
Nature Publishing Group
Non-patent literature
Publications
Reviewing status
Peer reviewed